| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Recruiting | One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS NCT07448935 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatm NCT07448779 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | BE.Amycon Biobank & Data Registry UZ Leuven NCT07172243 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloi NCT06649695 | European Myeloma Network B.V. | Phase 2 |
| Not Yet Recruiting | Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis NCT07055724 | Nanjing IASO Biotechnology Co., Ltd. | Phase 2 |
| Recruiting | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis NCT07079423 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Teclistamab in Previously Treated AL Amyloidosis NCT06935162 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394 | Peking University People's Hospital | N/A |
| Recruiting | The Norwegian Immunotherapy in Multiple Myeloma Study NCT06855121 | St. Olavs Hospital | — |
| Not Yet Recruiting | BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction The NCT06769555 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis NCT06569147 | Brigham and Women's Hospital | Phase 1 / Phase 2 |
| Recruiting | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have N NCT06022939 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis NCT05145816 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Unknown | Amyloidosis Incidence in High-Risk Cardiac Device Patients NCT06186167 | Midwest Heart & Vascular Specialists | — |
| Withdrawn | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (AL NCT05486481 | Alfred Chung, MD | Phase 1 / Phase 2 |
| Recruiting | Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979 | Jin Lu, MD | N/A |
| Recruiting | A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloido NCT06205953 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial NCT05898646 | Mayo Clinic | Phase 2 |
| Recruiting | Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis NCT05184088 | Life Molecular Imaging GmbH | Phase 3 |
| Recruiting | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis NCT05451771 | Rajshekhar Chakraborty, MD | Phase 1 / Phase 2 |
| Unknown | A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab NCT05277493 | Peking Union Medical College Hospital | — |
| Unknown | Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Bet NCT05066607 | Intergroupe Francophone du Myelome | Phase 2 |
| Withdrawn | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease NCT04984330 | Weill Medical College of Cornell University | EARLY_Phase 1 |
| Completed | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis NCT05199337 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies NCT05028374 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis NCT04895917 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 2 |
| Active Not Recruiting | Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945 | Emory University | Phase 1 |
| Active Not Recruiting | Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Pre NCT04270175 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis NCT04617925 | Stichting European Myeloma Network | Phase 2 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES NCT04512235 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES NCT04504825 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Terminated | A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light NCT04115956 | Oncopeptides AB | Phase 1 |
| Completed | Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis NCT04392960 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis NCT04304144 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | A Registry of AL Amyloidosis (ReAL) NCT04839003 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Completed | A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe NCT04937777 | European Myeloma Network B.V. | — |
| Active Not Recruiting | Ixazomib Maintenance Study in Patients With AL Amyloidosis NCT03618537 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis NCT03431896 | The Cleveland Clinic | — |
| Active Not Recruiting | Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple My NCT03315026 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Study in Subjects With Light Chain (AL) Amyloidosis NCT03154047 | Prothena Biosciences Ltd. | Phase 2 |
| Completed | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis NCT03236792 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Completed | Daratumumab for the Treatment of Patients With AL Amyloidosis NCT02841033 | Boston Medical Center | Phase 1 / Phase 2 |
| Terminated | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis NCT03000660 | Tufts Medical Center | Phase 1 |
| Completed | The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyl NCT02632786 | Prothena Biosciences Ltd. | Phase 2 |
| Terminated | Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis NCT02613182 | Prothena Biosciences Ltd. | Phase 2 |
| Completed | Quality of Life (QOL) Registry for Patients With AL Amyloidosis NCT02574676 | Prothena Biosciences Ltd. | — |
| Terminated | Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib NCT02489500 | Boston Medical Center | Phase 3 |
| Completed | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis NCT02245867 | Alexion Pharmaceuticals, Inc. | Phase 1 |
| Completed | Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis NCT01222260 | Columbia University | Phase 2 |
| Completed | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042 | Massachusetts General Hospital | N/A |
| Completed | A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis NCT01570387 | Boston Medical Center | Phase 1 / Phase 2 |
| Recruiting | Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource NCT01408225 | Ohio State University Comprehensive Cancer Center | — |
| Completed | A Trial for Systemic Light-chain (AL) Amyloidosis NCT01277016 | European Myeloma Network B.V. | Phase 3 |
| Enrolling By Invitation | Autologous Stem Cell Transplantation for Patients With AL Amyloidosis NCT04210791 | Nanjing University School of Medicine | — |
| Completed | Allo SCT in Amyloidosis Non-interventional Study NCT02257905 | European Society for Blood and Marrow Transplantation | — |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | Radioimmunoimaging of Light Chain (AL) Amyloidosis NCT01815086 | University of Tennessee | Phase 1 |
| Completed | Radioimmunoimaging of AL Amyloidosis NCT01409148 | University of Tennessee | Phase 1 |